Haemonetics Inks Software Deal

Haemonetics Corp. (HAE - Analyst Report) yesterday announced that it has entered into a deal with Blood Centers of America Inc. (“BCA”), a cooperative of community blood centers, which will provide BCA members access to Haemonetics’ blood management software.
 
Specifically, the agreement provides the BCA member’s access to Prelude and Interlude, modules of Haemonetics' integrated Symphony set of products that are designed to automate blood bank operations. Furthermore, BCA members will also have access to Haemonetics’ eQue automated interview and assessment donor screening system.
 
The eQue automated interview and assessment donor screening system is a donor registration and assessment tool designed to assist blood banks and plasma centers in determining a person’s eligibility to donate blood. 
 
We feel that this deal will benefit BCA members in a significant manner and will enhance the donation experience for both staff and donors.
 
This is the second big deal this month for Haemonetics, the market leader in developing and manufacturing blood collection and processing technology. Earlier this month, the company acquired the blood collection and processing business of Engineering and Research Associates Inc., commonly known as SEBRA. The transaction, worth $12.5 million in cash, is expected to be completed in a few months time. The SEBRA acquisition expands the vista of Haemonetics’ product offerings and increases its top-line. Furthermore, it strengthens the company’s position in the blood collection market. Haemonetics is developing an automated whole blood collection system and expects to launch it in late fiscal 2011.
 
Haemonetics operates in a very competitive environment, both for manual and automated systems, which includes big players like Baxter International Inc. (BAX - Analyst Report), Abbott Laboratories (ABT - Analyst Report) and Medtronic Inc. (MDT - Analyst Report).

Read the full analyst report on HAE

Read the full analyst report on BAX

Read the full analyst report on ABT

Read the full analyst report on MDT